Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

28.85
-0.2600-0.89%
Volume:469.32K
Turnover:13.63M
Market Cap:2.11B
PE:-122.43
High:29.48
Open:29.19
Low:28.74
Close:29.11
Loading ...

Kiniksa Pharmaceuticals International plc Conducted Annual Shareholders Meeting

Reuters
·
Yesterday

Chairman & CEO Sanj K. Patel Reports Disposal of Common Shares of Kiniksa Pharmaceuticals International plc

Reuters
·
29 May

Chairman & CEO Sanj K. Patel Reports Disposal of Kiniksa Pharmaceuticals Common Shares

Reuters
·
23 May

Eben Tessari, COO, Reports Disposal of Common Shares in Kiniksa Pharmaceuticals International plc

Reuters
·
22 May

Chairman & CEO Sanj K. Patel Reports Disposal of Common Shares of Kiniksa Pharmaceuticals International plc

Reuters
·
16 May

Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Evercore ISI

TIPRANKS
·
13 May

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

GlobeNewswire
·
30 Apr

An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued

Simply Wall St.
·
30 Apr

Kiniksa Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
30 Apr

Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating

MT Newswires Live
·
30 Apr

Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday

Benzinga
·
29 Apr

Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases

MT Newswires Live
·
29 Apr

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Zacks
·
29 Apr

Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q1 EPS $0.11, vs. FactSet Est of $0.13 per Share

MT Newswires Live
·
29 Apr

Kiniksa Pharmaceuticals Q1 GAAP EPS $0.11 Misses $0.14 Estimate, Sales $137.78M Miss $140.68M Estimate

Benzinga
·
29 Apr

BRIEF-Kiniksa Pharmaceuticals Q1 EPS USD 0.12

Reuters
·
29 Apr

Kiniksa Pharmaceuticals International Plc: Expects 2025 Arcalyst Net Product Revenue of Between $590 Million and $605 Million

THOMSON REUTERS
·
29 Apr

Kiniksa Pharmaceuticals Q1 Pretax Profit USD 15.565 Million

THOMSON REUTERS
·
29 Apr

Kiniksa Pharmaceuticals International Plc: Kpl-387 Phase 2/3 Clinical Trial in Recurrent Pericarditis on Track to Initiate in Mid-2025

THOMSON REUTERS
·
29 Apr

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

GlobeNewswire
·
29 Apr